Alderton W K, Cooper C E, Knowles R G
In Vitro Pharmacology Department, GlaxoSmithKline Research and Development, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Biochem J. 2001 Aug 1;357(Pt 3):593-615. doi: 10.1042/0264-6021:3570593.
This review concentrates on advances in nitric oxide synthase (NOS) structure, function and inhibition made in the last seven years, during which time substantial advances have been made in our understanding of this enzyme family. There is now information on the enzyme structure at all levels from primary (amino acid sequence) to quaternary (dimerization, association with other proteins) structure. The crystal structures of the oxygenase domains of inducible NOS (iNOS) and vascular endothelial NOS (eNOS) allow us to interpret other information in the context of this important part of the enzyme, with its binding sites for iron protoporphyrin IX (haem), biopterin, L-arginine, and the many inhibitors which interact with them. The exact nature of the NOS reaction, its mechanism and its products continue to be sources of controversy. The role of the biopterin cofactor is now becoming clearer, with emerging data implicating one-electron redox cycling as well as the multiple allosteric effects on enzyme activity. Regulation of the NOSs has been described at all levels from gene transcription to covalent modification and allosteric regulation of the enzyme itself. A wide range of NOS inhibitors have been discussed, interacting with the enzyme in diverse ways in terms of site and mechanism of inhibition, time-dependence and selectivity for individual isoforms, although there are many pitfalls and misunderstandings of these aspects. Highly selective inhibitors of iNOS versus eNOS and neuronal NOS have been identified and some of these have potential in the treatment of a range of inflammatory and other conditions in which iNOS has been implicated.
本综述聚焦于过去七年中一氧化氮合酶(NOS)在结构、功能及抑制方面取得的进展,在此期间,我们对这个酶家族的理解有了实质性的进展。现在已经有了从一级结构(氨基酸序列)到四级结构(二聚化、与其他蛋白质的结合)各个层面的酶结构信息。诱导型NOS(iNOS)和血管内皮NOS(eNOS)加氧酶结构域的晶体结构,使我们能够在酶的这一重要部分的背景下解读其他信息,包括其与铁原卟啉IX(血红素)、生物蝶呤、L-精氨酸以及许多与之相互作用的抑制剂的结合位点。NOS反应的确切性质、其机制及其产物仍然存在争议。生物蝶呤辅因子的作用现在越来越清晰,新出现的数据表明存在单电子氧化还原循环以及对酶活性的多种变构效应。从基因转录到酶本身的共价修饰和变构调节,NOS在各个层面的调节都已有描述。已经讨论了多种NOS抑制剂,它们在抑制位点和机制、时间依赖性以及对各个同工型的选择性方面以不同方式与酶相互作用,尽管在这些方面存在许多陷阱和误解。已经鉴定出了对iNOS相对于eNOS和神经元NOS具有高度选择性的抑制剂,其中一些在治疗一系列涉及iNOS的炎症和其他病症方面具有潜力。